Pharmacokinetics and central nervous system effects of the novel dopamine D 3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state

Journal of Psychopharmacology

Volumn 26, Issue 2, 2012, Pages 303-314

  Te Beek, E T ^a   ZoethoutR W M , ^a   Bani, M S G ^b   Andorn, A ^b   Iavarone, L ^b   Klaassen, E S ^a   Fina, P ^b   Van Gerven, J M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b GSK   (Italy)

Author keywords

Addiction; alcohol; dopamine D 3 receptor; GSK598809; interaction; pharmacodynamics; pharmacokinetics; substance abuse

Indexed keywords

ALCOHOL; CYTOCHROME P450 2E1; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GSK 598809; PLACEBO; PROLACTIN; UNCLASSIFIED DRUG;

ADAPTIVE BEHAVIOR; ADULT; AGED; AKATHISIA; ALCOHOLISM; AREA UNDER THE CURVE; ARTICLE; BODY EQUILIBRIUM; CATHETER COMPLICATION; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG SCREENING; DRUNKENNESS; DYSMENORRHEA; EYE MOVEMENT; FATIGUE; HUMAN; INJECTION SITE PAIN; LEARNING TEST; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUTH DISCOMFORT; NAUSEA; NORMAL HUMAN; PHARYNX DISCOMFORT; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SACCADIC EYE MOVEMENT; SINGLE DRUG DOSE; SKIN MANIFESTATION; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; VOMITING; WORD RECOGNITION; XEROSTOMIA;

ADULT; CENTRAL NERVOUS SYSTEM; CROSS-OVER STUDIES; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; ETHANOL; EYE MOVEMENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROLACTIN; PSYCHOMOTOR PERFORMANCE; RECEPTORS, DOPAMINE D3;

EID: 84856442281     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111431750     Document Type: Article

References (67)

1. Albanese A, Altavista MC, Rossi P. Organization of central nervous system dopaminergic pathways. J Neural Transm Suppl. 1986 ; 22: 3-17
2. Baloh RW, Sills AW, Kumley WE, Honrubia V. Quantitative measurement of saccade amplitude, duration, and velocity. Neurology. 1975 ; 25: 1065-1070
3. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 ; 154: 672-676 (Pubitemid 19154942)
4. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001 ; 22: 724-763 (Pubitemid 34214293)
5. Bittencourt PR, Wade P, Smith AT, Richens A. Benzodiazepines impair smooth pursuit eye movements. Br J Clin Pharmacol. 1983 ; 15: 259-262 (Pubitemid 13184404)
6. Bond A, Lader M. Use of analog scales in rating subjective feelings. Br J Med Psychol. 1974 ; 47 (SEP). 211-218
7. Borland RG, Nicholson AN. Visual motor co-ordination and dynamic visual acuity. Br J Clin Pharmacol. 1984 ; 18: 69S - 72S (Pubitemid 15184105)
8. Buckman MT, Peake GT. Estrogen potentiation of phenothiazine-induced prolactin secretion in man. J Clin Endocrinol Metab. 1973 ; 37: 977-980
9. Buckman MT, Peake GT, Srivastava LS. Endogenous estrogen modulates phenothiazine stimulated prolactin secretion. J Clin Endocrinol Metab. 1976 ; 43: 901-906
10. Caine SB, Koob GF. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science. 1993 ; 260: 1814-1816
11. Cami J, Farre M. Drug addiction. N Engl J Med. 2003 ; 349 (10). 975-986
12. de Haas SL, Franson KL, Schmitt JA, et al. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol. 2009 ; 23: 625-632
13. de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol. 2001 ; 51: 119-132 (Pubitemid 32219735)
14. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988 ; 85 (14). 5274-5278
15. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000 ; 80: 1523-1631
16. Gijsman HJ, van Gerven JM, Tieleman MC, et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol. 1998 ; 18: 289-295 (Pubitemid 28353871)
17. Grunder G, Wetzel H, Schlosser R, et al. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry. 1999 ; 45: 89-97 (Pubitemid 29049209)
18. 3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology. 1999 ; 20: 60-80 (Pubitemid 29010341)
19. 3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev. 2005 ; 49: 77-105 (Pubitemid 40800164)
20. 3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res. 1994 ; 648: 222-228
21. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry. 2005 ; 162: 1414-1422 (Pubitemid 41105555)
22. Hyman SE, Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci. 2001 ; 2: 695-703 (Pubitemid 33674815)
23. 3 receptor antagonists as therapeutic agents. Drug Discov Today. 2005 ; 10: 917-925 (Pubitemid 40922790)
24. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003 ; 28: 69-82 (Pubitemid 36332230)
25. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science. 1988 ; 242: 715-723
26. Koob GF, Nestler EJ. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci. 1997 ; 9: 482-497 (Pubitemid 27363951)
27. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron. 1998 ; 21 (3). 467-476 (Pubitemid 28475499)
28. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol. 1992 ; 19: 603-606
29. 3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res. 1993 ; 18: 187-192
30. 3 receptor and drug dependence: effects on reward or beyond?. Neuropharmacology. 2005 ; 49: 525-541 (Pubitemid 41169976)
31. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev. 1997 ; 49: 231-252 (Pubitemid 27414914)
32. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev. 1997 ; 77: 517-544 (Pubitemid 27184347)
33. Liem-Moolenaar M, Gray FA, de Visser SJ, et al. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J Psychopharmacol. 2010a ; 24: 73-82
34. Liem-Moolenaar M, Rad M, Zamuner S, et al. Central nervous system effects of the interaction between risperidone (single dose) and the 5HT6 antagonist SB742457 (repeated doses) in healthy males. Br J Clin Pharmacol. 2011 ; 71: 907-916
35. Liem-Moolenaar M, te Beek ET, de Kam ML, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol. 2010b ; 24: 1697-1708
36. Meltzer HY, Busch DA, Fang VS. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res. 1983 ; 9: 271-283 (Pubitemid 13002816)
37. Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 1976 ; 33: 279-286
38. Moore RY, Bloom FE. Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu Rev Neurosci. 1978 ; 1: 129-169
39. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988 ; 39: 1172-1177
40. 3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci U S A. 1994 ; 91: 11271-11275 (Pubitemid 24349668)
41. Nestler EJ. Is there a common molecular pathway for addiction?. Nat Neurosci. 2005 ; 8: 1445-1449 (Pubitemid 41573654)
42. Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology. 1971 ; 10: 181-191
43. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999 ; 35: S67 - S73
44. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci Biobehav Rev. 2006 ; 30: 215-238 (Pubitemid 41821810)
45. Rey A L'examen clinique en psychologie. Paris: Presses Universitaires de France ; 1964 :
46. Schmitt JA, Jorissen BL, Sobczak S, et al. Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. J Psychopharmacol. 2000 ; 14: 21-29 (Pubitemid 30156534)
47. 3 receptor antagonist. Biol Psychiatry. 2010 ; 68: 392-399
48. 3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse. 2006 ; 60: 205-211 (Pubitemid 44036715)
49. 3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res. 1997 ; 45: 335-339 (Pubitemid 27170712)
50. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970 ; 212: 11-19
51. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002 ; 22: 109-114 (Pubitemid 34289384)
52. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci. 1996 ; 16: 6100-6106 (Pubitemid 26313985)
53. C] raclopride and positron emission tomography. Accepted for publication. Journal of Psychopharmacology. 2011a ;:
54. te Beek ET, Moerland M, De Boer P, Van Nueten L, De Kam ML, Burggraaf J, et al. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681. Journal of Psychopharmacology. 2011b ;:
55. van Steveninck AL, Gieschke R, Schoemaker HC, et al. Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. Psychopharmacology (Berl). 1993 ; 110: 471-478 (Pubitemid 23074572)
56. van Steveninck AL, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther. 1991 ; 50: 172-180
57. van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol. 1999 ; 13: 10-17 (Pubitemid 29141271)
58. Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol. 1999 ; 13: 337-345 (Pubitemid 30055177)
59. Volkow ND, Fowler JS, Wang GJ. Positron emission tomography and single-photon emission computed tomography in substance abuse research. Semin Nucl Med. 2003 ; 33: 114-128 (Pubitemid 36577054)
60. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology. 2009 ; 56: 3-8
61. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004 ; 9: 557-569 (Pubitemid 38850435)
62. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol. 2007 ; 64: 1575-1579 (Pubitemid 350106758)
63. Wode-Helgodt B, Eneroth P, Fyro B, Gullberg B, Sedvall G. Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatr Scand. 1977 ; 56: 280-293 (Pubitemid 8190611)
64. Wright BM. A simple mechanical ataxia-meter. J Physiol. 1971 ; 218 (1). 27P - 28P
65. Yasui-Furukori N, Saito M, Nakagami T, et al. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010 ; 34: 537-540
66. Zoethout RW, Schoemaker RC, Zuurman L, et al. Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers. Br J Clin Pharmacol. 2009 ; 68: 524-534
67. Zoethout RW, van Gerven JM, Dumont GJ, et al. A comparative study of two methods for attaining constant alcohol levels. Br J Clin Pharmacol. 2008 ; 66: 674-681